Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biometrics' Q2 Revenues Rise 96 Percent

NEW YORK (GenomeWeb News) – Pacific Biometrics, a Seattle-based CRO and multiplex assay developer, today reported that its second-quarter revenues increased nearly 100 percent and it swung to a profit from a loss.

The firm brought in total revenues of $3.2 million for the three-month period ended Dec. 31, compared to revenues of $1.6 million for the second quarter of 2007.

Pacific Biometrics posted a profit of $976,671, or $.05 per share, for the quarter, compared to a net loss of $818,219, or $.04 per share, for the second quarter of 2007.

The company did not list any R&D costs for either period, but reported that its SG&A expenses declined around 8 percent to $1.1 million from $1.2 million.

Pacific Biometrics finished the quarter with $1.3 million in cash and cash equivalents.

Ron Helm, CEO of Pacific Biometrics, said that the firm's cash position and lack of debt "better positions the company to execute its strategic plan for continued growth in the specialty laboratory business and to allocate increased resources to support the growth of our Pacific Biomarkers subsidiary."

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.